VasoDynamics strengthens Board and management team with key appointments
Building a strong team of industry experts as clinical programmes progress
• Paul Stainer, Director and Chief Financial Officer
• Roger Widdowson, Non-Executive Director
10th January 2022 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, today announces two key appointments to support the management team.
Ningfeng Fiona Li, CEO of VasoDynamics, said:
“With our initial clinical programmes progressing rapidly and as we build a strong portfolio of follow-on candidates, supported by our recent successful funding found, it is vitally important that we have the financial and industry expertise to support the management team as our programmes progress into clinical stage. We are delighted to announce the appointments of Paul Stainer and Roger Widdowson, both of whom bring invaluable experience to the Board as we enter our next phase of clinical and commercial development.”
Paul Stainer, Director and Chief Financial Officer
Paul is a seasoned executive, with over 35 years of experience in the pharmaceutical sector, having held Board and/or senior financial, commercial and operations positions in several global companies including Wyeth, Pfizer and Otsuka. Over a long career, Paul has been played a key role in launching many new products in numerous therapeutic areas. Both in finance and operations he has championed transformation programmes and managed licensing deals and alliances with strategic partners.
Paul Stainer said “I am delighted to have joined VasoDynamics at such an exciting time of the company’s development, with several programmes entering late-stage and clinical development phase. I am looking forward to working with the executive team as we accelerate the out-reach to potential commercial partners.”
Roger Widdowson, Non-Executive Director
Roger recently retired from KPMG after 33 years, where he served for over 20 years as Partner in Deal Advisory, advising on over numerous transactions in the Healthcare & Life Sciences sector in the UK, USA, Germany, France and Australia. For over 10 years, Roger served on the KPMG Global Healthcare Steering Committee, which drives strategy and growth across the firm’s international healthcare practice across 45 countries. Between March 2020 and September 2021 he advised the NHS on the commercial aspects of a £2bn Covid response project.
Roger Widdowson said “I am delighted to join VasoDynamics, which is developing exciting products to help patients undergoing cancer treatments by preventing some of the most common side-effects. This is truly meaningful work, targeting an area of substantial unmet need and with significant commercial potential.”
For enquiries, please contact:
Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve the most effective protection of normal tissue during cancer treatment whilst enhancing anti-cancer therapy efficacy.
